Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Cancer|Solid Tumor|Melanoma|Renal Cell Carcinoma|Triple-negative Breast Cancer|Non Small Cell Lung Cancer|Squamous Cell Carcinoma of the Head and Neck|Carcinoma|MSI-High
Interventions: BIOLOGICAL: ST-067|BIOLOGICAL: Obinutuzumab 25 MG/1 ML Intravenous Solution [GAZYVA]|BIOLOGICAL: pembrolizumab
Sponsor: Simcha IL-18, Inc.
Collaborators: Merck Sharp & Dohme LLC